抗高血压药与晚年认知衰退和神经病理学的关系
Ajay Sood1, Ana Werneck Capuano2, Rupal Mehta1
1Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 25, 2025
概括
老年人使用抗高血压药物与认知衰退的减缓和阿尔茨海默氏症病理学的减少有关,特别是较低的团. 这表明这些常见的血压药物对大脑衰老有潜在的保护作用.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗高血压药 (AHT) 被广泛使用,但它们对认知衰老和神经病理学的影响尚不清楚.
- 了解这些关联对于公共卫生至关重要,因为高血压和认知能力下降在老年人群中都很普遍.
研究的目的:
- 调查抗高血压药物使用与老年人认知衰退之间的关系.
- 检查AHT使用与神经病理标志物之间的关联,包括死后脑组织中的tau团密度.
主要方法:
- 这是一项前性研究,涉及3300多名没有基线痴呆症的社区老年人,每年对平均8.6年的认知变化进行评估.
- 从1800多名已故参与者的脑组织进行神经病理学分析,以量化神经退行性和脑血管病理.
主要成果:
- 使用AHT显著与更高的基线全球认知和全球认知,情节性记忆和语义记忆下降的速度较慢有关.
- 在尸检队列中,AHT使用与降低团密度相关,这是阿尔茨海默病的关键标志物,但不是其他主要的神经病理.
- 这些发现甚至在调整血压水平和其他并发性疾病后仍然存在.
结论:
- 晚年使用抗高血压药物与保持认知功能和减缓认知衰退有关.
- 使用AHT与阿尔茨海默氏病的病理学减少有关,特别是较低的纠负担.
- 这些结果表明,抗高血压药在衰老中可能起到神经保护作用.
相关概念视频
Cognitive Development During Adulthood
780
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
780
Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
Drug Dosing: Geriatric Patients
227
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
227
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560


